Detalhe da pesquisa
1.
PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma.
Haematologica
; 109(2): 567-577, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496441
2.
Epigenetics in multiple myeloma: From mechanisms to therapy.
Semin Cancer Biol
; 51: 101-115, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28962927
3.
One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.
Epigenomes
; 5(4)2021 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968247
4.
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Oncotarget
; 8(6): 10213-10224, 2017 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28052011
5.
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.
Oncotarget
; 8(61): 103731-103743, 2017 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29262596
6.
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Oncotarget
; 7(6): 6809-23, 2016 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755663